Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/13/2019 08/14/2019 08/15/2019 08/16/2019 08/19/2019 Date
94.2(c) 92.89(c) 93.31(c) 94.74(c) 95.22(c) Last
2 963 953 4 850 032 2 385 612 2 675 096 1 983 230 Volume
+0.14% -1.39% +0.45% +1.53% +0.51% Change
More quotes
Financials (USD)
Sales 2019 17 366 M
EBIT 2019 10 140 M
Net income 2019 6 470 M
Debt 2019 1 302 M
Yield 2019 -
Sales 2020 19 178 M
EBIT 2020 11 133 M
Net income 2020 7 559 M
Finance 2020 5 310 M
Yield 2020 -
P/E ratio 2019 10,9x
P/E ratio 2020 9,15x
EV / Sales2019 3,96x
EV / Sales2020 3,24x
Capitalization 67 486 M
More Financials
Company
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.8%); - other (0.2%): cellular therapy products and biological materials for implants, for... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
08/19Who is next in big pharma's merger spree?
RE
08/19CELGENE CORPORATION : - U.S. FDA Approves INREBIC as First New Treatment in Near..
AQ
08/16CELGENE : FDA Grants Approval to Celgene's Impact for Bone Marrow Disorder Treat..
DJ
08/16CELGENE : U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Near..
BU
07/30CELGENE : DE/ Management's Discussion and Analysis of Financial Condition and Re..
AQ
07/30CELGENE : Second-Quarter Revenue at Celgene Surpasses Wall Street Targets
DJ
07/30CELGENE : 2Q Earnings Snapshot
AQ
07/30CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
AQ
07/30CELGENE : Reports Second Quarter 2019 Operating and Financial Results
BU
07/29Pfizer to spinoff, merge off-patent drugs unit with Mylan
RE
More news
Analyst Recommendations on CELGENE CORPORATION
More recommendations
Stock Trading Strategies
CELGENE CORPORATION - 03/28
In an accumulation phase
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
08/19ALLERGAN : Form 8.3 - Allergan Plc
DJ
08/19NOVARTIS : to answer U.S. Senate demand for data manipulation details
RE
08/19NOVARTIS : CEO Under Fire Over Drug Data
DJ
08/18NOVARTIS : executive sold shares before drug data manipulation made public
RE
08/18NOVARTIS : CEO Battles Fallout From Data Manipulation
DJ
More sector news : Pharmaceuticals - NEC
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 100,14  $
Last Close Price 95,22  $
Spread / Highest target 26,0%
Spread / Average Target 5,17%
Spread / Lowest Target -11,8%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION48.57%67 146
JOHNSON & JOHNSON2.48%346 681
ROCHE HOLDING LTD.12.24%238 299
MERCK AND COMPANY12.80%217 785
NOVARTIS17.81%204 677
PFIZER-19.40%191 651